489P Organ-on-Chip: An in vitro model to study the efficacy and prediction of adjuvant therapy in lung cancer patient-derived cells

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for 11.6% of cancer diagnoses and 18.4% of cancer mortality. Non-small cell lung cancer (NSCLC) represents 85% of cases and is often driven by genetic alterations, including EGFR mutations in 16% of patients. Despite targeted therapies, overall survival remains poor, emphasizing the need for more effective, personalized treatments. In early-stage lung cancer, adjuvant chemotherapy is given after surgery to reduce recurrence, but its variable efficacy limits its predictive value.